U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

Glioblastoma, IDH-Wildtype

MedGen UID:
308044
•Concept ID:
C1514422
•
Neoplastic Process
Synonyms: Primary Glioblastoma; Primary Glioblastoma, IDH-Wildtype

Definition

A glioblastoma that arises de novo. It is more commonly seen in older patients. Mutations in IDH1 or IDH2 genes are not present. [from NCI]

Professional guidelines

PubMed

Effects of Long-Term Temozolomide Treatment on Glioblastoma and Astrocytoma WHO Grade 4 Stem-like Cells.
Feldheim J, Kessler AF, Feldheim JJ, Schulz E, Wend D, Lazaridis L, Kleinschnitz C, Glas M, Ernestus RI, Brandner S, Monoranu CM, Löhr M, Hagemann C
Int J Mol Sci 2022 May 7;23(9) doi: 10.3390/ijms23095238. PMID: 35563629Free PMC Article
Therapy for Diffuse Astrocytic and Oligodendroglial Tumors in Adults: ASCO-SNO Guideline.
Mohile NA, Messersmith H, Gatson NT, Hottinger AF, Lassman A, Morton J, Ney D, Nghiemphu PL, Olar A, Olson J, Perry J, Portnow J, Schiff D, Shannon A, Shih HA, Strowd R, van den Bent M, Ziu M, Blakeley J
J Clin Oncol 2022 Feb 1;40(4):403-426. Epub 2021 Dec 13 doi: 10.1200/JCO.21.02036. PMID: 34898238
Clinical utility of targeted next-generation sequencing assay in IDH-wildtype glioblastoma for therapy decision-making.
Lim-Fat MJ, Youssef GC, Touat M, Iorgulescu JB, Whorral S, Allen M, Rahman R, Chukwueke U, McFaline-Figueroa JR, Nayak L, Lee EQ, Batchelor TT, Arnaout O, Peruzzi PP, Chiocca EA, Reardon DA, Meredith D, Santagata S, Beroukhim R, Bi WL, Ligon KL, Wen PY
Neuro Oncol 2022 Jul 1;24(7):1140-1149. doi: 10.1093/neuonc/noab282. PMID: 34878541Free PMC Article

Recent clinical studies

Etiology

Dynamic contrast-enhanced MRI radiomics model predicts epidermal growth factor receptor amplification in glioblastoma, IDH-wildtype.
Sohn B, Park K, Ahn SS, Park YW, Choi SH, Kang SG, Kim SH, Chang JH, Lee SK
J Neurooncol 2023 Sep;164(2):341-351. Epub 2023 Sep 10 doi: 10.1007/s11060-023-04435-y. PMID: 37689596
A novel chemokine-based signature for prediction of prognosis and therapeutic response in glioma.
Fan W, Wang D, Li G, Xu J, Ren C, Sun Z, Wang Z, Ma W, Zhao Z, Bao Z, Jiang T, Zhang Y
CNS Neurosci Ther 2022 Dec;28(12):2090-2103. Epub 2022 Aug 19 doi: 10.1111/cns.13944. PMID: 35985661Free PMC Article
Temozolomide and Radiotherapy versus Radiotherapy Alone in Patients with Glioblastoma, IDH-wildtype: Post Hoc Analysis of the EORTC Randomized Phase III CATNON Trial.
Tesileanu CMS, Sanson M, Wick W, Brandes AA, Clement PM, Erridge SC, Vogelbaum MA, Nowak AK, Baurain JF, Mason WP, Wheeler H, Chinot OL, Gill S, Griffin M, Rogers L, Taal W, Rudà R, Weller M, McBain C, van Linde ME, Aldape K, Jenkins RB, Kros JM, Wesseling P, von Deimling A, Hoogstrate Y, de Heer I, Atmodimedjo PN, Dubbink HJ, Brouwer RWW, van IJcken WFJ, Cheung KJ, Golfinopoulos V, Baumert BG, Gorlia T, French PJ, van den Bent MJ
Clin Cancer Res 2022 Jun 13;28(12):2527-2535. doi: 10.1158/1078-0432.CCR-21-4283. PMID: 35275197Free PMC Article
The survival outcomes of molecular glioblastoma IDH-wildtype: a multicenter study.
Ramos-Fresnedo A, Pullen MW, Perez-Vega C, Domingo RA, Akinduro OO, Almeida JP, Suarez-Meade P, Marenco-Hillembrand L, Jentoft ME, Bendok BR, Trifiletti DM, Chaichana KL, Porter AB, Quiñones-Hinojosa A, Burns TC, Kizilbash SH, Middlebrooks EH, Sherman WJ
J Neurooncol 2022 Mar;157(1):177-185. Epub 2022 Feb 17 doi: 10.1007/s11060-022-03960-6. PMID: 35175545
An Integrative Model of Cellular States, Plasticity, and Genetics for Glioblastoma.
Neftel C, Laffy J, Filbin MG, Hara T, Shore ME, Rahme GJ, Richman AR, Silverbush D, Shaw ML, Hebert CM, Dewitt J, Gritsch S, Perez EM, Gonzalez Castro LN, Lan X, Druck N, Rodman C, Dionne D, Kaplan A, Bertalan MS, Small J, Pelton K, Becker S, Bonal D, Nguyen QD, Servis RL, Fung JM, Mylvaganam R, Mayr L, Gojo J, Haberler C, Geyeregger R, Czech T, Slavc I, Nahed BV, Curry WT, Carter BS, Wakimoto H, Brastianos PK, Batchelor TT, Stemmer-Rachamimov A, Martinez-Lage M, Frosch MP, Stamenkovic I, Riggi N, Rheinbay E, Monje M, Rozenblatt-Rosen O, Cahill DP, Patel AP, Hunter T, Verma IM, Ligon KL, Louis DN, Regev A, Bernstein BE, Tirosh I, Suvà ML
Cell 2019 Aug 8;178(4):835-849.e21. Epub 2019 Jul 18 doi: 10.1016/j.cell.2019.06.024. PMID: 31327527Free PMC Article

Diagnosis

A novel chemokine-based signature for prediction of prognosis and therapeutic response in glioma.
Fan W, Wang D, Li G, Xu J, Ren C, Sun Z, Wang Z, Ma W, Zhao Z, Bao Z, Jiang T, Zhang Y
CNS Neurosci Ther 2022 Dec;28(12):2090-2103. Epub 2022 Aug 19 doi: 10.1111/cns.13944. PMID: 35985661Free PMC Article
The survival outcomes of molecular glioblastoma IDH-wildtype: a multicenter study.
Ramos-Fresnedo A, Pullen MW, Perez-Vega C, Domingo RA, Akinduro OO, Almeida JP, Suarez-Meade P, Marenco-Hillembrand L, Jentoft ME, Bendok BR, Trifiletti DM, Chaichana KL, Porter AB, Quiñones-Hinojosa A, Burns TC, Kizilbash SH, Middlebrooks EH, Sherman WJ
J Neurooncol 2022 Mar;157(1):177-185. Epub 2022 Feb 17 doi: 10.1007/s11060-022-03960-6. PMID: 35175545
Therapy for Diffuse Astrocytic and Oligodendroglial Tumors in Adults: ASCO-SNO Guideline.
Mohile NA, Messersmith H, Gatson NT, Hottinger AF, Lassman A, Morton J, Ney D, Nghiemphu PL, Olar A, Olson J, Perry J, Portnow J, Schiff D, Shannon A, Shih HA, Strowd R, van den Bent M, Ziu M, Blakeley J
J Clin Oncol 2022 Feb 1;40(4):403-426. Epub 2021 Dec 13 doi: 10.1200/JCO.21.02036. PMID: 34898238
Diffuse Astrocytoma, IDH-Wildtype: A Dissolving Diagnosis.
Hasselblatt M, Jaber M, Reuss D, Grauer O, Bibo A, Terwey S, Schick U, Ebel H, Niederstadt T, Stummer W, von Deimling A, Paulus W
J Neuropathol Exp Neurol 2018 Jun 1;77(6):422-425. doi: 10.1093/jnen/nly012. PMID: 29444314
The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary.
Louis DN, Perry A, Reifenberger G, von Deimling A, Figarella-Branger D, Cavenee WK, Ohgaki H, Wiestler OD, Kleihues P, Ellison DW
Acta Neuropathol 2016 Jun;131(6):803-20. Epub 2016 May 9 doi: 10.1007/s00401-016-1545-1. PMID: 27157931

Therapy

Carmustine wafer implantation for supratentorial glioblastomas, IDH-wildtype in "extreme" neurosurgical conditions.
Roux A, Aboubakr O, Elia A, Moiraghi A, Benevello C, Fathallah H, Parraga E, Oppenheim C, Chretien F, Dezamis E, Zanello M, Pallud J
Neurosurg Rev 2023 Jun 17;46(1):140. doi: 10.1007/s10143-023-02052-x. PMID: 37329341
Effects of Long-Term Temozolomide Treatment on Glioblastoma and Astrocytoma WHO Grade 4 Stem-like Cells.
Feldheim J, Kessler AF, Feldheim JJ, Schulz E, Wend D, Lazaridis L, Kleinschnitz C, Glas M, Ernestus RI, Brandner S, Monoranu CM, Löhr M, Hagemann C
Int J Mol Sci 2022 May 7;23(9) doi: 10.3390/ijms23095238. PMID: 35563629Free PMC Article
Temozolomide and Radiotherapy versus Radiotherapy Alone in Patients with Glioblastoma, IDH-wildtype: Post Hoc Analysis of the EORTC Randomized Phase III CATNON Trial.
Tesileanu CMS, Sanson M, Wick W, Brandes AA, Clement PM, Erridge SC, Vogelbaum MA, Nowak AK, Baurain JF, Mason WP, Wheeler H, Chinot OL, Gill S, Griffin M, Rogers L, Taal W, Rudà R, Weller M, McBain C, van Linde ME, Aldape K, Jenkins RB, Kros JM, Wesseling P, von Deimling A, Hoogstrate Y, de Heer I, Atmodimedjo PN, Dubbink HJ, Brouwer RWW, van IJcken WFJ, Cheung KJ, Golfinopoulos V, Baumert BG, Gorlia T, French PJ, van den Bent MJ
Clin Cancer Res 2022 Jun 13;28(12):2527-2535. doi: 10.1158/1078-0432.CCR-21-4283. PMID: 35275197Free PMC Article
Therapy for Diffuse Astrocytic and Oligodendroglial Tumors in Adults: ASCO-SNO Guideline.
Mohile NA, Messersmith H, Gatson NT, Hottinger AF, Lassman A, Morton J, Ney D, Nghiemphu PL, Olar A, Olson J, Perry J, Portnow J, Schiff D, Shannon A, Shih HA, Strowd R, van den Bent M, Ziu M, Blakeley J
J Clin Oncol 2022 Feb 1;40(4):403-426. Epub 2021 Dec 13 doi: 10.1200/JCO.21.02036. PMID: 34898238
Prognostic importance of temozolomide-induced neutropenia in glioblastoma, IDH-wildtype patients.
Saito T, Sugiyama K, Hama S, Yamasaki F, Takayasu T, Nosaka R, Muragaki Y, Kawamata T, Kurisu K
Neurosurg Rev 2018 Apr;41(2):621-628. Epub 2017 Sep 9 doi: 10.1007/s10143-017-0903-3. PMID: 28887717

Prognosis

A novel chemokine-based signature for prediction of prognosis and therapeutic response in glioma.
Fan W, Wang D, Li G, Xu J, Ren C, Sun Z, Wang Z, Ma W, Zhao Z, Bao Z, Jiang T, Zhang Y
CNS Neurosci Ther 2022 Dec;28(12):2090-2103. Epub 2022 Aug 19 doi: 10.1111/cns.13944. PMID: 35985661Free PMC Article
Temozolomide and Radiotherapy versus Radiotherapy Alone in Patients with Glioblastoma, IDH-wildtype: Post Hoc Analysis of the EORTC Randomized Phase III CATNON Trial.
Tesileanu CMS, Sanson M, Wick W, Brandes AA, Clement PM, Erridge SC, Vogelbaum MA, Nowak AK, Baurain JF, Mason WP, Wheeler H, Chinot OL, Gill S, Griffin M, Rogers L, Taal W, Rudà R, Weller M, McBain C, van Linde ME, Aldape K, Jenkins RB, Kros JM, Wesseling P, von Deimling A, Hoogstrate Y, de Heer I, Atmodimedjo PN, Dubbink HJ, Brouwer RWW, van IJcken WFJ, Cheung KJ, Golfinopoulos V, Baumert BG, Gorlia T, French PJ, van den Bent MJ
Clin Cancer Res 2022 Jun 13;28(12):2527-2535. doi: 10.1158/1078-0432.CCR-21-4283. PMID: 35275197Free PMC Article
The survival outcomes of molecular glioblastoma IDH-wildtype: a multicenter study.
Ramos-Fresnedo A, Pullen MW, Perez-Vega C, Domingo RA, Akinduro OO, Almeida JP, Suarez-Meade P, Marenco-Hillembrand L, Jentoft ME, Bendok BR, Trifiletti DM, Chaichana KL, Porter AB, Quiñones-Hinojosa A, Burns TC, Kizilbash SH, Middlebrooks EH, Sherman WJ
J Neurooncol 2022 Mar;157(1):177-185. Epub 2022 Feb 17 doi: 10.1007/s11060-022-03960-6. PMID: 35175545
Therapy for Diffuse Astrocytic and Oligodendroglial Tumors in Adults: ASCO-SNO Guideline.
Mohile NA, Messersmith H, Gatson NT, Hottinger AF, Lassman A, Morton J, Ney D, Nghiemphu PL, Olar A, Olson J, Perry J, Portnow J, Schiff D, Shannon A, Shih HA, Strowd R, van den Bent M, Ziu M, Blakeley J
J Clin Oncol 2022 Feb 1;40(4):403-426. Epub 2021 Dec 13 doi: 10.1200/JCO.21.02036. PMID: 34898238
Genomic and Phenotypic Characterization of a Broad Panel of Patient-Derived Xenografts Reflects the Diversity of Glioblastoma.
Vaubel RA, Tian S, Remonde D, Schroeder MA, Mladek AC, Kitange GJ, Caron A, Kollmeyer TM, Grove R, Peng S, Carlson BL, Ma DJ, Sarkar G, Evers L, Decker PA, Yan H, Dhruv HD, Berens ME, Wang Q, Marin BM, Klee EW, Califano A, LaChance DH, Eckel-Passow JE, Verhaak RG, Sulman EP, Burns TC, Meyer FB, O'Neill BP, Tran NL, Giannini C, Jenkins RB, Parney IF, Sarkaria JN
Clin Cancer Res 2020 Mar 1;26(5):1094-1104. Epub 2019 Dec 18 doi: 10.1158/1078-0432.CCR-19-0909. PMID: 31852831Free PMC Article

Clinical prediction guides

Dynamic contrast-enhanced MRI radiomics model predicts epidermal growth factor receptor amplification in glioblastoma, IDH-wildtype.
Sohn B, Park K, Ahn SS, Park YW, Choi SH, Kang SG, Kim SH, Chang JH, Lee SK
J Neurooncol 2023 Sep;164(2):341-351. Epub 2023 Sep 10 doi: 10.1007/s11060-023-04435-y. PMID: 37689596
Clinical characteristics and radiological features of glioblastoma, IDH-wildtype, grade 4 with histologically lower-grade gliomas.
Motomura K, Kibe Y, Ohka F, Aoki K, Yamaguchi J, Saito R
Brain Tumor Pathol 2023 Apr;40(2):48-55. Epub 2023 Mar 29 doi: 10.1007/s10014-023-00458-5. PMID: 36988764
A novel chemokine-based signature for prediction of prognosis and therapeutic response in glioma.
Fan W, Wang D, Li G, Xu J, Ren C, Sun Z, Wang Z, Ma W, Zhao Z, Bao Z, Jiang T, Zhang Y
CNS Neurosci Ther 2022 Dec;28(12):2090-2103. Epub 2022 Aug 19 doi: 10.1111/cns.13944. PMID: 35985661Free PMC Article
Temozolomide and Radiotherapy versus Radiotherapy Alone in Patients with Glioblastoma, IDH-wildtype: Post Hoc Analysis of the EORTC Randomized Phase III CATNON Trial.
Tesileanu CMS, Sanson M, Wick W, Brandes AA, Clement PM, Erridge SC, Vogelbaum MA, Nowak AK, Baurain JF, Mason WP, Wheeler H, Chinot OL, Gill S, Griffin M, Rogers L, Taal W, Rudà R, Weller M, McBain C, van Linde ME, Aldape K, Jenkins RB, Kros JM, Wesseling P, von Deimling A, Hoogstrate Y, de Heer I, Atmodimedjo PN, Dubbink HJ, Brouwer RWW, van IJcken WFJ, Cheung KJ, Golfinopoulos V, Baumert BG, Gorlia T, French PJ, van den Bent MJ
Clin Cancer Res 2022 Jun 13;28(12):2527-2535. doi: 10.1158/1078-0432.CCR-21-4283. PMID: 35275197Free PMC Article
Therapy for Diffuse Astrocytic and Oligodendroglial Tumors in Adults: ASCO-SNO Guideline.
Mohile NA, Messersmith H, Gatson NT, Hottinger AF, Lassman A, Morton J, Ney D, Nghiemphu PL, Olar A, Olson J, Perry J, Portnow J, Schiff D, Shannon A, Shih HA, Strowd R, van den Bent M, Ziu M, Blakeley J
J Clin Oncol 2022 Feb 1;40(4):403-426. Epub 2021 Dec 13 doi: 10.1200/JCO.21.02036. PMID: 34898238

Recent systematic reviews

Therapy for Diffuse Astrocytic and Oligodendroglial Tumors in Adults: ASCO-SNO Guideline.
Mohile NA, Messersmith H, Gatson NT, Hottinger AF, Lassman A, Morton J, Ney D, Nghiemphu PL, Olar A, Olson J, Perry J, Portnow J, Schiff D, Shannon A, Shih HA, Strowd R, van den Bent M, Ziu M, Blakeley J
J Clin Oncol 2022 Feb 1;40(4):403-426. Epub 2021 Dec 13 doi: 10.1200/JCO.21.02036. PMID: 34898238

Supplemental Content

Table of contents

    Practice guidelines

    • PubMed
      See practice and clinical guidelines in PubMed. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.
    • Bookshelf
      See practice and clinical guidelines in NCBI Bookshelf. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Related information

    • PMC Articles
      Related information in PubMed Central Links
    • PubMed
      Related literature resources in PubMed

    Recent activity

    Clear Turn Off Turn On

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...